"Alanine Transaminase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.
| Descriptor ID |
D000410
|
| MeSH Number(s) |
D08.811.913.477.700.100
|
| Concept/Terms |
Alanine Transaminase- Alanine Transaminase
- Transaminase, Alanine
- Glutamic-Alanine Transaminase
- Glutamic Alanine Transaminase
- Transaminase, Glutamic-Alanine
- Alanine-2-Oxoglutarate Aminotransferase
- Alanine 2 Oxoglutarate Aminotransferase
- Aminotransferase, Alanine-2-Oxoglutarate
- Alanine Aminotransferase
- Aminotransferase, Alanine
- Glutamic-Pyruvic Transaminase
- Glutamic Pyruvic Transaminase
- Transaminase, Glutamic-Pyruvic
|
Below are MeSH descriptors whose meaning is more general than "Alanine Transaminase".
Below are MeSH descriptors whose meaning is more specific than "Alanine Transaminase".
This graph shows the total number of publications written about "Alanine Transaminase" by people in this website by year, and whether "Alanine Transaminase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2011 | 0 | 3 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alanine Transaminase" by people in Profiles.
-
Fractalkine suppression during hepatic encephalopathy promotes neuroinflammation in mice. J Neuroinflammation. 2016 08 26; 13(1):198.
-
Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. Carcinogenesis. 2015 Feb; 36(2):243-8.
-
Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther. 2014 Oct; 40(8):949-54.
-
Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart. 2014 Oct; 100(19):1511-6.
-
Mathematical modelling of chronic acetaminophen metabolism and liver injury. Math Med Biol. 2014 Sep; 31(3):302-17.
-
Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med. 2013 Apr; 19(4):418-20.
-
Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst. 2012 Oct 17; 104(20):1599-611.
-
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology. 2011 Nov; 54(5):1527-37.
-
S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcohol Clin Exp Res. 2011 Nov; 35(11):1960-5.
-
Chronic maternal protein deprivation in mice is associated with overexpression of the cohesin-mediator complex in liver of their offspring. J Nutr. 2011 Dec; 141(12):2106-12.